PMID- 29285389 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20201001 IS - 2049-9450 (Print) IS - 2049-9469 (Electronic) IS - 2049-9450 (Linking) VI - 7 IP - 6 DP - 2017 Dec TI - Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco-regional control? PG - 1135-1141 LID - 10.3892/mco.2017.1434 [doi] AB - This prospective study aimed to estimate the efficacy of sorafenib therapy after transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC). Between July 2011 and March 2013, 17 patients were enrolled, 11 of whom received sorafenib therapy. Patients who previously received TACE for HCC and whose disease progressed within a six-month period were given 400-800 mg sorafenib orally, once or twice daily, within the 3 weeks after a second TACE (sorafenib after TACE group). The response to treatment, time to progression (TTP), overall survival (OS), and adverse events (AEs) were recorded. Of the 113 patients who underwent initial TACE for unresectable HCC between January 1995 and January 2013, 23 patients were selected who were treated with TACE alone, and for whom the interval between the second and third TACE treatments was <6 months (TACE alone group). The interval (TTP) was calculated between the third and fourth TACE treatments, then TTP was compared among the three groups: Sorafenib after TACE for > or <4 months; and TACE alone. During a median follow-up period of 34.4 months (range, 5.9-51.7 months) in both groups receiving sorafenib after TACE, sorafenib prolonged TTP (3.9 months) and OS (34.4 months). It was demonstrated that sorafenib use for >4 months prolonged TTP (5.7 months) significantly compared with use for <4 months (3.0 months) (P=0.002). The OS of patients given sorafenib for >4 months (35.9 months) was longer than that of patients who received the drug for <4 months (17.2 months), but this difference was not significant. In the TACE alone group, the median TTP between the third and fourth TACE treatments was 4.3 months. TTP decreased among the groups in the following order: Sorafenib for >4 months, TACE alone, and sorafenib for <4 months. There were three AEs of grade 3 in the present study. Two patients demonstrated a decrease in liver reserve function following sorafenib treatment, but improved immediately after sorafenib administration was stopped. Sorafenib induction early after TACE for unresectable HCC was generally well tolerated and significantly improved TTP. Further studies are required to confirm the safety and efficacy of this combination therapy. FAU - Tamai, Tsutomu AU - Tamai T AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. FAU - Kumagai, Kotaro AU - Kumagai K AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. FAU - Sakae, Haruka AU - Sakae H AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. FAU - Onishi, Hiroka AU - Onishi H AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. FAU - Tabu, Kazuaki AU - Tabu K AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. FAU - Tabu, Eriko AU - Tabu E AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. FAU - Muromachi, Kaori AU - Muromachi K AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. FAU - Saishoji, Akiko AU - Saishoji A AD - Department of Hepatology, Kagoshima Teishin Hospital, Kagoshima 890-8798, Japan. FAU - Oda, Kohei AU - Oda K AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. FAU - Mawatari, Seiichi AU - Mawatari S AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. FAU - Moriuchi, Akihiro AU - Moriuchi A AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. FAU - Sakurai, Kazuhiro AU - Sakurai K AD - Department of Hepatology, Kagoshima Teishin Hospital, Kagoshima 890-8798, Japan. FAU - Ido, Akio AU - Ido A AD - Department of Digestive and Lifestyle Disease, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890-8520, Japan. LA - eng PT - Journal Article DEP - 20171002 PL - England TA - Mol Clin Oncol JT - Molecular and clinical oncology JID - 101613422 PMC - PMC5740826 OTO - NOTNLM OT - hepatocellular carcinoma OT - sorafenib OT - transarterial chemoembolization EDAT- 2017/12/30 06:00 MHDA- 2017/12/30 06:01 PMCR- 2017/10/02 CRDT- 2017/12/30 06:00 PHST- 2017/05/12 00:00 [received] PHST- 2017/09/28 00:00 [accepted] PHST- 2017/12/30 06:00 [entrez] PHST- 2017/12/30 06:00 [pubmed] PHST- 2017/12/30 06:01 [medline] PHST- 2017/10/02 00:00 [pmc-release] AID - MCO-0-0-1434 [pii] AID - 10.3892/mco.2017.1434 [doi] PST - ppublish SO - Mol Clin Oncol. 2017 Dec;7(6):1135-1141. doi: 10.3892/mco.2017.1434. Epub 2017 Oct 2.